Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the... Drugs R D (2018) 18:163 https://doi.org/10.1007/s40268-018-0234-z CORRECTION Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 1 2 1 1 • • • • Sebastiano Buti Maddalena Donini Melissa Bersanelli Alessia Gattara 1 2 Francesco Leonardi Rodolfo Passalacqua Published online: 28 May 2018 The Author(s) 2018 Open Access This article is distributed under the terms of the Correction to: Creative Commons Attribution-NonCommercial 4.0 International Drugs R D https://doi.org/10.1007/s40268-017-0209-5 License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any In the Original Publication of the article, In Introduction medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and part, 7th line, the value ‘‘5–100 nM’’ has been published indicate if changes were made. incorrectly. The correct value should read as ‘‘Plasma concentration of 50–100 ng/ml’’. In the Original Publica- tion of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown below: Table 2 Delivered treatment, dose reductions and interruptions Sunitinib 4/2 schedule Sunitinib modified schedule Median time from start to switch, months (range) 2.9 (1.4–16.5) – Median duration of treatment after switch, months (range) – 9.2 (0.5–32.4) Mean actual daily dose intensity, mg (range) 46.1 (20.8–50.0) 44.3 (17.9–71.8) Mean relative dose intensity, % (range) 92.3 (42–100) 88.7 (36–144) Total cycles, number 88 164 Median cycles, number (range) 2 (1–11) 5 (1–20) Patients with a dose reduction, number (%) 3 (12) 3 (12) Patients with a dose interruption, number (%) 7 (28) 12 (48) Number of dose interruptions corrected for number of cycles (%) 0.10 (10) 0.11 (11) Patients still on treatment, number (%) – 2 (16) The original article can be found online at https://doi.org/10.1007/ s40268-017-0209-5. & Melissa Bersanelli bersamel@libero.it Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs in R&D Springer Journals

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/correction-to-feasibility-safety-and-efficacy-of-an-alternative-h6yY0FTb2s
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
1174-5886
eISSN
1179-6901
D.O.I.
10.1007/s40268-018-0234-z
Publisher site
See Article on Publisher Site

Abstract

Drugs R D (2018) 18:163 https://doi.org/10.1007/s40268-018-0234-z CORRECTION Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 1 2 1 1 • • • • Sebastiano Buti Maddalena Donini Melissa Bersanelli Alessia Gattara 1 2 Francesco Leonardi Rodolfo Passalacqua Published online: 28 May 2018 The Author(s) 2018 Open Access This article is distributed under the terms of the Correction to: Creative Commons Attribution-NonCommercial 4.0 International Drugs R D https://doi.org/10.1007/s40268-017-0209-5 License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any In the Original Publication of the article, In Introduction medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and part, 7th line, the value ‘‘5–100 nM’’ has been published indicate if changes were made. incorrectly. The correct value should read as ‘‘Plasma concentration of 50–100 ng/ml’’. In the Original Publica- tion of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown below: Table 2 Delivered treatment, dose reductions and interruptions Sunitinib 4/2 schedule Sunitinib modified schedule Median time from start to switch, months (range) 2.9 (1.4–16.5) – Median duration of treatment after switch, months (range) – 9.2 (0.5–32.4) Mean actual daily dose intensity, mg (range) 46.1 (20.8–50.0) 44.3 (17.9–71.8) Mean relative dose intensity, % (range) 92.3 (42–100) 88.7 (36–144) Total cycles, number 88 164 Median cycles, number (range) 2 (1–11) 5 (1–20) Patients with a dose reduction, number (%) 3 (12) 3 (12) Patients with a dose interruption, number (%) 7 (28) 12 (48) Number of dose interruptions corrected for number of cycles (%) 0.10 (10) 0.11 (11) Patients still on treatment, number (%) – 2 (16) The original article can be found online at https://doi.org/10.1007/ s40268-017-0209-5. & Melissa Bersanelli bersamel@libero.it Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy

Journal

Drugs in R&DSpringer Journals

Published: May 28, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off